| 靶向药物治疗套细胞淋巴瘤的研究进展 |
| |
| 引用本文： | 赵志强. 靶向药物治疗套细胞淋巴瘤的研究进展[J]. 白血病．淋巴瘤, 2015, 0(10): 632-635. DOI: 10.3760/cma.j.issn.1009-9921.2015.10.019 |
| |
| 作者姓名： | 赵志强 |
| |
| 作者单位： | 山西医科大学附属肿瘤医院血液科,太原,030013 |
| |
| 摘 要： | 套细胞淋巴瘤(MCL)是一种少见的非霍奇金淋巴瘤亚型.MCL临床表现有两种类型:一种为惰性表现,病情进展缓慢;另一种为侵袭性表现,病程进展迅速.近年,一些用于MCL治疗的新靶向药物已经问世.这些靶向药物较常规化疗提高了对复发/难治性MCL的疗效,其治疗MCL的靶点为B细胞淋巴瘤表面抗原、B细胞受体信号和肿瘤细胞微环境等.文章介绍了MCL靶向药物的研究进展.
|
| 关 键 词： | 淋巴瘤,套细胞 靶向药物 |
Research progress of targeted agents in the treatment of mantle cell lymphoma |
| |
| Abstract: | Mantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin lymphoma.The MCL is classified into two subtypes, some patients have a chronic/indolent course and the others have a more aggressive course and short survival.In recent years, some novel therapeutic target agents for MCL have reports.These target agents achieve efficacy comparable to conventional chemotherapy in relapsed/refractory MCL.Therapeutic targents for MCL include the surface antigens of B-cell lymphoma, B-cell receptor signaling, DNA damage response pathway and the cellular microenviroment.This review focused on the recent research progress of target agents in the treatment of MCL. |
| |
| Keywords: | Lymphoma,mantle cell Target agent |
| 本文献已被 万方数据 等数据库收录！ |
|
